phrykt

Ani Pharmaceuticals Inc (ANIP): who owns it and who trades it

As of Nov 16, 2026, ANIP insiders reported 47 open-market sales worth $13.6M and no purchases in the last 12 months, with 45% of the sale value made under pre-set 10b5-1 plans. The largest seller was Nikhil Lalwani (CEO), with $5.4M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ani Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ANIP

305 funds and institutions reported ANIP shares worth $1.9B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $245M.

10 largest owners, by value

BlackRock, Inc.$245M
Soleus Capital Management, L.P.$71.8M
Vanguard Capital Management LLC$69.4M
State Street Corp$68.9M
Tang Capital Management LLC$58.6M
Dimensional Fund Advisors LP$51.6M
American Century Companies Inc$47.6M
Arrowstreet Capital, Limited Partnership$46.5M
Global Alpha Capital Management Ltd.$46.2M
Geode Capital Management, LLC$44.4M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.2.96M–$245M+8%
Soleus Capital Management, L.P.867,760–$71.8M+6%
Vanguard Capital Management LLC838,224–$69.4M+2%
State Street Corp831,647–$68.9M+8%
Tang Capital Management LLC707,500–$58.6MNo change
Dimensional Fund Advisors LP623,463–$51.6M+17%
American Century Companies Inc574,474–$47.6M+200%
Arrowstreet Capital, Limited Partnership562,016–$46.5M-0%
Global Alpha Capital Management Ltd.558,003–$46.2M+54%
Geode Capital Management, LLC536,407–$44.4M+10%
Millennium Management LLC507,207–$42M-14%
Nuveen, LLC415,024–$34.4M+3%
Vanguard Portfolio Management LLC407,281–$33.7M+8%
Ranger Investment Management, L.P.343,150–$28.4M-5%
Deutsche Bank Ag\323,443–$26.8M+1%
Invesco Ltd.309,233–$25.6M-5%
UBS Group AG297,539–$24.6M-40%
Kennedy Capital Management LLC295,938–$24.5M+1%
Ameriprise Financial Inc287,382–$23.8M+6%
Nomura Asset Management International Inc.287,206–$23.8M-0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ANIP insiders reported $0 of open-market purchases and $13.6M of sales. 45% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$13.6M
47 trades, 11 people
Sales under a 10b5-1 plan
45%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 13, 2026

Purchases and sales by month

$5.7M$5.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Meredith CookVice presidentSale plan500$70.80$35.4KForm 4
Oct 29, 2026Stephen P. CareyCFOSale plan2,850$72.87$208KForm 4
Oct 15, 2026Nikhil LalwaniCEOSale plan5,400$71.89$388KForm 4
Oct 13, 2026Meredith CookVice presidentSale plan500$73.59$36.8KForm 4
Sep 29, 2026Stephen P. CareyCFOSale plan2,850$73.00$208KForm 4
Sep 15, 2026Nikhil LalwaniCEOSale plan5,400$71.00$383KForm 4
Sep 14, 2026Meredith CookVice presidentSale plan500$70.79$35.4KForm 4
Sep 11, 2026Jeanne ThomaDirectorSale plan1,000$71.53$71.5KForm 4
Aug 31, 2026Stephen P. CareyCFOSale plan2,850$72.80$207KForm 4
Aug 25, 2026Nikhil LalwaniCEOSale plan5,400$74.30$401KForm 4
Aug 13, 2026Meredith CookVice presidentSale plan500$75.48$37.7KForm 4
Aug 10, 2026Ori GutwergVice presidentSale3,162$77.00$243KForm 4
Jul 29, 2026Stephen P. CareyCFOSale plan2,850$81.36$232KForm 4
Jul 13, 2026Meredith CookVice presidentSale plan500$81.84$40.9KForm 4
Jul 2, 2026Stephen P. CareyCFOSale plan3,313$86.00$285KForm 4
Jun 29, 2026Stephen P. CareyCFOSale plan2,850$84.12$240KForm 4
Jun 12, 2026Meredith CookVice presidentSale plan500$82.03$41KForm 4
Jun 8, 2026Thomas HaugheyDirectorSale plan2,000$80.88$162KForm 4
Jun 5, 2026Stephen P. CareyCFOSale plan3,312$80.00$265KForm 4
May 13, 2026Patrick D WalshDirectorSale10,000$80.63$806KForm 4
May 13, 2026Meredith CookVice presidentSale plan500$78.16$39.1KForm 4
May 12, 2026Thomas Andrew RowlandVice presidentSale459$79.21$36.4KForm 4
May 12, 2026Ori GutwergVice presidentSale2,772$79.50$220KForm 4
May 11, 2026Patrick D WalshDirectorSale3,973$80.75$321KForm 4
May 11, 2026Nikhil LalwaniCEOSale55,000$77.57$4.3MForm 4
Apr 13, 2026Meredith CookVice presidentSale plan500$77.95$39KForm 4
Mar 13, 2026Christopher MutzHEAD OF RARE DISEASESale plan3,162$71.64$227KForm 4
Mar 13, 2026Meredith CookVice presidentSale plan500$72.62$36.3KForm 4
Mar 11, 2026Thomas Andrew RowlandVice presidentSale4,772$74.91$357KForm 4
Mar 9, 2026Christopher MutzHEAD OF RARE DISEASESale plan3,602$74.18$267KForm 4
Mar 9, 2026Krista DavisVice presidentSale plan5,087$74.13$377KForm 4
Mar 6, 2026Christopher MutzHEAD OF RARE DISEASESale plan2,121$74.22$157KForm 4
Mar 6, 2026Krista DavisVice presidentSale plan1,485$75.00$111KForm 4
Mar 5, 2026Stephen P. CareyCFOSale4,000$75.56$302KForm 4
Mar 5, 2026Stephen P. CareyCFOSale3,312$75.42$250KForm 4
Mar 3, 2026Ori GutwergVice presidentSale2,060$76.50$158KForm 4
Mar 3, 2026Patrick D WalshDirectorSale6,000$74.23$445KForm 4
Mar 2, 2026Christopher MutzHEAD OF RARE DISEASESale plan417$74.00$30.9KForm 4
Feb 20, 2026Christopher MutzHEAD OF RARE DISEASESale plan5,323$78.02$415KForm 4
Feb 20, 2026Krista DavisVice presidentSale plan1,730$77.99$135KForm 4
Feb 19, 2026Krista DavisVice presidentSale plan2,084$77.53$162KForm 4
Feb 13, 2026Meredith CookVice presidentSale plan500$76.80$38.4KForm 4
Feb 12, 2026Christopher MutzHEAD OF RARE DISEASESale plan7,032$76.55$538KForm 4
Jan 13, 2026Meredith CookVice presidentSale plan500$84.33$42.2KForm 4
Dec 18, 2025Krista DavisVice presidentSale plan1,622$82.40$134KForm 4
Dec 12, 2025Meredith CookVice presidentSale plan400$82.32$32.9KForm 4
Dec 5, 2025Renee P TannenbaumDirectorSale1,800$81.15$146KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Nikhil LalwaniPRESIDENT & CEO, Director–$5.4MOct 15, 2026
Stephen P. CareySVP & CFO–$2.2MOct 29, 2026
Christopher MutzHEAD OF RARE DISEASE–$1.6MMar 13, 2026
Patrick D WalshDirector–$1.6MMay 13, 2026
Krista DavisSVP, CHIEF HR OFFICER–$919KMar 9, 2026
Ori GutwergSVP, GENERICS–$621KAug 10, 2026
Meredith CookSR. VP, GENERAL COUNSEL & SEC.–$455KNov 13, 2026
Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS–$394KMay 12, 2026
Thomas HaugheyDirector–$162KJun 8, 2026
Renee P TannenbaumDirector–$146KDec 5, 2025
Jeanne ThomaDirector–$71.5KSep 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ANIP short interest

3.58M ANIP shares are sold short. Over the last 12 reports the number of shares short went down 1%.

As of Oct 30, 2026, 3.58M ANIP shares were sold short, up 3.2% from the report before. At the average daily volume of 301,720 shares, buying them all back would take about 11.9 trading days (days to cover).

Shares short

3.58MMay 15Oct 303.82M

Days to cover

11.9May 15Oct 3012.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.58M–+3%301,72011.9
Oct 15, 20263.47M–-1%343,76010.1
Sep 30, 20263.49M–+40%487,3567.2
Sep 15, 20262.49M–-26%334,8807.4
Aug 31, 20263.36M–-2%364,9129.2
Aug 14, 20263.42M–+47%464,2637.4
Jul 31, 20262.33M–-31%252,4289.2
Jul 15, 20263.37M–-2%307,31911.0
Jun 30, 20263.44M–+8%365,4309.4
Jun 15, 20263.20M–-4%293,39310.9
May 29, 20263.32M–-8%336,4559.9
May 15, 20263.62M–+2%469,5037.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ani Pharmaceuticals company events

Ani Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, auditor). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AgreementOn Novemb er 4, 2 026, ANI Pharmaceuticals, Inc. entered into a credit agreement relating to a 364-day senior bridge facility, with the lenders named therein and JPMorgan Chase Bank, N.A, as administrative agent. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Aug 24, 2026LeadershipThe Board of Directors of ANI Pharmaceuticals, Inc. appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company’s 2027 annual meeting of stockholders. Filing
  4. Aug 7, 2026ResultsReleased financial results. Filing
  5. May 21, 2026LeadershipANI Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026. Filing
  6. May 13, 2026AnnouncementShared information with investors. Filing
  7. May 8, 2026ResultsReleased financial results. Filing
  8. Apr 7, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  9. Mar 3, 2026AnnouncementShared information with investors. Filing
  10. Feb 27, 2026ResultsReleased financial results. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Dec 1, 2025LeadershipPatrick D. Walsh notified the Company that he will not seek re-election as a director at the Company’s 2026 Annual Meeting of Stockholders, but will continue to serve as a director until the Annual Meeting. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ani Pharmaceuticals financials

Famous investors that hold ANIP

3 of the 50 well-known investors we track reported holding ANIP in their latest 13F filing. The largest position is Israel Englander's, worth $17.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026243,146$17.7M0.0%-52%
Ken Griffin · Citadel AdvisorsQ3 2026109,331$7.9M0.0%+14%
Jim Simons · Renaissance TechnologiesQ3 202618,000$1.3M0.0%-72%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Ani Pharmaceuticals Inc (ANIP) stock

Who owns the most ANIP stock?

The largest reported owner of Ani Pharmaceuticals Inc (ANIP) is BlackRock, Inc.. In total, 305 funds and institutions reported holding ANIP at the end of Q2 2026. See the largest owners.

Are ANIP insiders buying or selling?

In the last 12 months, ANIP insiders reported no open-market purchases and 47 sales worth $13.6M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in ANIP?

As of Oct 30, 2026, 3.58M ANIP shares were sold short, up 3.2% from the report before. At the average daily volume of 301,720 shares, buying them all back would take about 11.9 trading days (days to cover). See the history.

Which famous investors hold ANIP?

3 of the 50 well-known investors we track reported ANIP in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $17.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.